Characteristics of 139 patients with newly diagnosed AL amyloidosis eligible for ASCT
| Variables . | Data . |
|---|---|
| Age, median (IQR), y | 56 (50-61) |
| Sex, male | 77 (55) |
| Organ involvement | |
| Heart | 66 (47) |
| Kidney | 104 (75) |
| Liver | 16 (11) |
| Soft tissues | 19 (14) |
| Autonomic nervous system | 6 (4) |
| Peripheral nervous system | 9 (6) |
| More than 2 organs involved | 15 (12) |
| Cardiac stage* | |
| I | 62 (45) |
| II | 71 (51) |
| IIIa | 3 (22) |
| IIIb | 0 (0) |
| NT-proBNP, median (IQR), ng/L | 360 (133-840) |
| Renal stage† | |
| I | 70 (51) |
| II | 69 (49) |
| III | 0 (0) |
| Proteinuria, median (IQR), g/24 h | 4.80 (0.67-7.00) |
| eGFR, median (IQR), mL/min/1.72 m2 | 84 (64 to >90) |
| Bone marrow plasma cells, median (IQR), % | 10 (6-15) |
| Variables . | Data . |
|---|---|
| Age, median (IQR), y | 56 (50-61) |
| Sex, male | 77 (55) |
| Organ involvement | |
| Heart | 66 (47) |
| Kidney | 104 (75) |
| Liver | 16 (11) |
| Soft tissues | 19 (14) |
| Autonomic nervous system | 6 (4) |
| Peripheral nervous system | 9 (6) |
| More than 2 organs involved | 15 (12) |
| Cardiac stage* | |
| I | 62 (45) |
| II | 71 (51) |
| IIIa | 3 (22) |
| IIIb | 0 (0) |
| NT-proBNP, median (IQR), ng/L | 360 (133-840) |
| Renal stage† | |
| I | 70 (51) |
| II | 69 (49) |
| III | 0 (0) |
| Proteinuria, median (IQR), g/24 h | 4.80 (0.67-7.00) |
| eGFR, median (IQR), mL/min/1.72 m2 | 84 (64 to >90) |
| Bone marrow plasma cells, median (IQR), % | 10 (6-15) |
Unless otherwise noted, data are n (%).
cTnI, cardiac troponin I; eGFR, estimated glomerular filtration rate; IQR, interquartile range; NT-proBNP, N-terminal natriuretic propeptide type B.
Cardiac stage is based on troponin level and NT-proBNP: thresholds for cTnI and NT-proBNP are <0.1 ng/mL and <332 ng/L, respectively. Stage I, cTnI <0.1 ng/mL and NT-proBNP <332 ng/L; stage II, cTnI >0.1 ng/mL or NT-proBNP >332 ng/L; stage IIIa, cTnI >0.1 ng/mL and NT-proBNP >332 ng/L but <8500 ng/L; and stage IIIb, cTnI >0.1 ng/mL and NT-proBNP >8500 ng/L.
Renal stage is based on proteinuria and eGFR levels: thresholds for proteinuria are >5 g/24 h and eGFR <50 mL/min/1.73 m2. Stage I, proteinuria ≤5 g/24 h and eGFR ≥50 mL/min/1.73 m2; stage II, proteinuria >5 g/24 h or eGFR <50 mL/min/1.73 m2; and stage III, proteinuria >5 g/24 h and eGFR <50 mL/min/1.73 m2.